Related Experiment Video

Updated: Sep 20, 2026

Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages
08:26

Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages

Published on: February 23, 2024

Future directions in the management of ovarian cancer

Mary L Disis1, Saul Rivkin

  • 1Department of Oncology, University of Washington, Box 356527, Seattle, WA 98195-6527, USA. ndisis@u.washington.edu

Hematology/Oncology Clinics of North America
|September 10, 2003
PubMed

Insights

Future ovarian cancer treatment will target oncogenic pathways to eliminate residual disease and prevent recurrence. This shift aims to manage ovarian cancer as a chronic condition rather than an imminently terminal disease.

Area of Science:

  • Oncology
  • Translational Medicine
  • Cancer Therapeutics

Background:

  • Ovarian cancer growth and invasion are driven by specific oncogenic pathways.
  • Current treatment paradigms for ovarian cancer require evolution to improve patient outcomes.
  • Minimal residual disease and drug resistance present significant challenges in ovarian cancer management.

Purpose of the Study:

  • To outline a future strategic approach for ovarian cancer treatment.
  • To emphasize the shift towards targeted therapies and novel treatment concepts.
  • To reframe the management of recurrent ovarian cancer.

Main Methods:

  • Defining oncogenic pathways involved in ovarian cancer at the molecular level.
  • Developing targeted therapies to inhibit these identified pathways.
  • Evaluating clinical efficacy of consolidation and maintenance regimens.
  • Exploring alternative treatment strategies for recurrent ovarian cancer.

Main Results:

  • The study proposes a paradigm shift in ovarian cancer treatment strategies.
  • Future approaches will focus on eliminating minimal residual disease post-primary therapy.
  • Consolidation and maintenance regimens will be clinically evaluated.
  • Recurrent ovarian cancer management will transition from cytotoxic approaches to disease control.

Conclusions:

  • Targeting oncogenic pathways offers a promising avenue for ovarian cancer treatment.
  • Eliminating minimal residual disease is key to achieving a cure.
  • Managing ovarian cancer as a chronic disease is a feasible future goal.
  • Novel therapeutic strategies are essential for overcoming treatment resistance and improving long-term survival.

More Related Videos

Surgical Techniques to Optimize Ovarian Reserve during Laparoscopic Cystectomy for Ovarian Endometrioma11:29

Surgical Techniques to Optimize Ovarian Reserve during Laparoscopic Cystectomy for Ovarian Endometrioma

Published on: January 22, 2022

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...